SCHEMBL860377

SCHEMBL860377

CC(C)(C)OC(=O)Nc1ccc(B2OC(C)(C)C(C)(C)O2)cn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 2/20 0.53
AAK1 Q2M2I8 2/20 0.50
USP30 Q70CQ3 2/20 0.49
PRMT5 O14744 1/20 0.47
WDR77 Q9BQA1 1/20 0.47
HIF1A Q16665 2/20 0.40
GSK3B P49841 2/20 0.39
DYRK1A Q13627 1/20 0.39
PDGFRB P09619 1/20 0.39
KDR P35968 1/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
BACE1 P56817 1/20 0.38
BACE2 Q9Y5Z0 1/20 0.38
NAMPT P43490 1/20 0.38
GRIN2B Q13224 1/20 0.38
HDAC1 Q13547 1/20 0.38
BCL2 P10415 1/20 0.37
GSK3A P49840 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3853382 0.93 DGAT1 (0.47) DGAT1AAK1USP30PRMT5WDR77
SCHEMBL3791054 0.87 DGAT1 (0.54) DGAT1AAK1USP30HIF1AGSK3B
SCHEMBL30400446 0.87 DGAT1 (0.54) DGAT1AAK1USP30HIF1AGSK3B
SCHEMBL1180976 0.84 AAK1 (0.47) DGAT1AAK1USP30PRMT5WDR77
SCHEMBL29967445 0.83 DGAT1 (0.50) DGAT1AAK1USP30PRMT5WDR77
SCHEMBL19195067 0.83 DGAT1 (0.50) DGAT1AAK1USP30PRMT5WDR77
SCHEMBL20227776 0.83 GSK3B (0.49) DGAT1AAK1USP30PRMT5WDR77
SCHEMBL2119494 0.83 DGAT1 (0.53) DGAT1AAK1USP30HIF1AGSK3B
SCHEMBL9979047 0.82 PRMT5 (0.48) DGAT1AAK1USP30PRMT5WDR77
SCHEMBL29393739 0.82 PRMT5 (0.48) DGAT1AAK1USP30PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036730-A Gαq/11 protein inhibitor with purine skeleton, and preparation method and application thereof 中山大学 2026-05-15 CN claimed
CN-122036730-A Gαq/11 protein inhibitor with purine skeleton, and preparation method and application thereof 中山大学 2026-05-15 CN disclosed
US-12600728-B2 Interleukin-17 inhibitors NOVARTIS AG (CH) 2026-04-14 US disclosed
US-20260014147-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2026-01-15 US disclosed
US-20250361244-A1 BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS AURIGENE ONCOLOGY LTD (IN) 2025-11-27 US disclosed
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 US disclosed
WO-2025235363-A1 CYCLIN-DEPENDENT KINASE 4 DEGRADERS BLUEPRINT MEDICINES CORPORATION (US) 2025-11-13 WO disclosed
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2025-11-06 US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 US disclosed
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-03 US disclosed
WO-2010135360-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed
US-20100074862-A1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS MAIER THOMAS 2010-03-25 US disclosed
US-7666868-B2 e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders 4SC AG (DE) 2010-02-23 US disclosed
EP-2078003-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2009-07-15 EP disclosed
EP-1861365-B1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2009-07-01 EP disclosed
US-20080176848-A1 e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders NYCOMED GMBH (DE) 2008-07-24 US disclosed
WO-2008054702-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-05-08 WO disclosed
EP-1861365-A1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS Nycomed GmbH (DE) 2007-12-05 EP disclosed
WO-2006097474-A1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS NYCOMED GMBH (DE) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, HRH2 DGAT1 140/4885AAK1 2010/4885USP30 657/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 DGAT1 1054/4885AAK1 1779/4885USP30 1139/4885
US-20080176848-A1 e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders HDAC1, H1-3, HDAC2 DGAT1 3947/4885AAK1 1343/4885USP30 862/4885
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, STAT1, STAT5B DGAT1 661/4885AAK1 1457/4885USP30 2781/4885
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 DGAT1 1208/4885AAK1 4091/4885USP30 4205/4885
US-20260014147-A1 STAT6 DEGRADERS STAT6, NCOR1, CBR1 DGAT1 1928/4885AAK1 3624/4885USP30 1865/4885
US-20100074862-A1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC3, HDAC2 DGAT1 4584/4885AAK1 3035/4885USP30 1030/4885
US-20250361244-A1 BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS IRAK4, IRAK3, IRAK1 DGAT1 4374/4885AAK1 579/4885USP30 1784/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 DGAT1 1054/4885AAK1 1779/4885USP30 1139/4885
US-12600728-B2 Interleukin-17 inhibitors IL17A, IL2, IL1B DGAT1 2928/4885AAK1 768/4885USP30 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.